

References to figure legends are in *italic type*

- abdominal teratomas 78
- adenocarcinoma, renal 19
- adenoma, hepatic 16, *1.23, 1.24*
  - Fanconi's anaemia 13, 16
- adrenal medulla, preterm, neuroblasts 46, *5.7, 5.8*
- alpha-fetoprotein (AFP)
  - hepatic teratomas 79
  - hepatocellular carcinoma 12
  - yolk sac tumours 72
- angioendothelioma, endovascular papillary 85
- angiofibroma, nasopharyngeal 97
- angiolymphoid hyperplasia, eosinophilia 84–5, *10.18, 10.19*
- angiomatoid malignant fibrous histiocytoma 111, *13.15, 13.16*
- Ann Arbor staging, Hodgkin's disease 38
- Askin's tumour 50, *6.2–6.6*
  - and Ewing's sarcoma 55, 58
- $\beta_2$ -microglobulin, osseous Ewing's sarcoma 58, *7.10*
- Beckwith–Wiedemann syndrome 26
- Birbeck granules, Langerhans cell histiocytosis 60, *8.4*
- bladder, urinary, pseudosarcomatous myoblastic proliferation 106
- blastema, renal, nodular 22, *2.12–2.20*
- blastoma, pulmonary 106
- BMRTC 28, 30
  - cord cells 28, *3.3*
  - differential diagnosis 33
  - entrapped nephrons 28, *3.6*
  - histological variations 28, 30, *3.7, 3.8*
  - pathological features 28, *3.1–3.6*
  - septal cells 28, *3.4*
  - ultrastructure 30
  - vascular pattern 28, *3.5*
  - Wilms' tumour differences 33
- bone
  - desmoplastic fibroma 96
  - eosinophilic granuloma 60
  - Ewing's sarcoma 55, 58, *7.1–7.6, 7.10, 7.11*
  - invasion, cranial fasciitis 114, *13.9*
  - Langerhans cell histiocytosis 62, *8.2, 8.3, 8.8–8.10*
  - metastasizing renal tumour of childhood (BMRTC) *see* BMRTC
  - neuroectodermal tumour 55
- brain tumours, MRTK-associated 31
- bronchiectasis, Langerhans cell histiocytosis 62, *8.14*
- Burkitt's lymphoma 19, 34–5, *4.5–4.10*
  - endemic/sporadic, clinical differences 34–5
  - intracytoplasmic neutral fat 35, *4.9*
  - lymphoid follicles 35, *4.10*
  - pyroninophilia 35, *4.8*
- capillary haemangiomas 81, *10.1–10.6*
  - cellularity/mitoses 81, *10.2*
  - lobular growth 81, *10.1*
  - maturation 81, *10.3, 10.4*
- catecholamine granules, neuroblastoma 46, *5.13, 5.14*
- cavernous haemangiomas 81, *10.7*
- cellular peripheral neural tumour (CPNT) 108
- central nervous system, Langerhans cell histiocytosis 63
- Charcot–Leyden crystals 60
- chloroma (granulocytic sarcoma) 39, *4.24*
- chondrosarcoma
  - embryonal, extraskelatal 111
  - myxoid, extraskelatal 111
- choristoma, neuromuscular 115
- chromogranin A, serum levels, neuroblastoma 47
- cirrhosis, hepatocellular carcinoma-associated 12–13
- CPDN *see* nephroblastoma, cystic
- cytotoxic histiocytosis *see* Rosai–Dorfman disease
- cytotrophoblastic cells, choriocarcinoma 72, *9.15*
- Dabska tumour 85
- dermatofibrosarcoma protuberans 110
- dermoids, ovarian 74, *9.24–9.27*
- desmin, rhabdomyosarcoma 103
- desmoplastic small-cell tumour 51, *6.11, 6.12*
- Drash syndrome 26
- dysgerminomas, ovarian 72, *9.11–9.13*
- ectomesenchymoma 51, *6.9, 6.10, 106*
- embryonal sarcoma, infantile 70, 72, *9.9, 9.10*
- endodermal sinus tumour 70, 72
- endothelial hyperplasia, papillary 85, *10.20, 10.21*
- enolase, serum levels, neuroblastoma 47
- eosinophilic granuloma, multiple focal 63
- epithelioid sarcoma 118
- Epstein–Barr virus
  - endemic Burkitt's lymphoma 34
  - infection, haemophagocytic syndrome 66
- epulis, granular cell 108, *110, 13.7*
- erythrophagocytic lymphohistiocytosis 66, *8.16–8.21*
- esthesioneuroblastoma 51
- Ewing's sarcoma
  - and Askin's tumour 55, 58
  - cytoplasmic glycogen 58, *7.11*
  - large-cell variant 58, *7.12*
  - osseous 55, *7.1–7.6*
    - chromosome karyotype 55, *7.6*
    - histogenesis 55
    - immunohistochemistry 58, *7.10*
  - prognosis 58
  - soft tissue 55, 58, *7.7–7.9*
    - imaging 55, *7.9*
    - immunohistochemistry 58
    - RMS differentiation 102
  - ultrastructure 58, *7.11*
- familial haemophagocytic lymphohistiocytosis (FHL) 66, *8.16–8.21*
- Fanconi's anaemia
  - hepatic adenoma 13, 16
  - hepatocellular carcinoma-associated 13
- fasciitis
  - cranial
    - bone invasion 114, *13.19*
    - of childhood 111, 114, *13.19–13.23*
    - nodular 111, *13.17, 13.18*
    - pseudosarcomatous 111, *13.17, 13.18*
- ferritin, serum levels, neuroblastoma 47
- fetal hydrops 74
- fibroblastoma, giant cell 110, *13.11, 13.12*
- fibrohistiocytic tumour, plexiform 110–11, *13.13, 13.14*
  - histological patterns 110
- fibroma
  - aponeurotic, calcifying 93, *11.14, 11.15*
  - desmoplastic, of bone 96
  - digital, recurring 92–3, *11.7–11.10*
  - tendon sheath 115
- fibromatosis 89
  - aggressive 96–7, *11.23, 11.24*
  - aponeurotic, juvenile (JAF) 93, *11.14, 11.15*
  - cartilage analogue 93, *11.14, 11.15*
  - colli 93, *11.13*
  - desmoid-type, infantile 96, *11.17–11.22*
  - diffuse congenital 89, 92, *11.1–11.3*
  - diffuse-type, infantile 96, *11.17–11.21*
  - digital
    - infantile 92–3, *11.7–11.10*
    - recurring, of childhood 92–3, *11.7–11.10*
- fibrosarcoma-like, congenital 96–7, *11.23, 11.24*
- generalized congenital 89, 92, *11.1–11.3*
- hyaline 93, 96, *11.16*

- hyalinica multiplex juvenalis 93, 96, 11.16  
inclusion body 92–3, 11.7–11.10  
intra-abdominal 96  
musculoaponeurotic 96, 11.22  
palmar and plantar 93, 11.11, 11.12  
fibrosarcoma, congenital–infantile 96–7, 11.23, 11.24  
metastases 97  
prognosis 97  
recurrence 97  
fibrous hamartoma, of infancy (FHI) 92, 11.4, 11.6  
fibula, Ewing's sarcoma 55, 7.1  
focal nodular hyperplasia (FNH), liver 16, 1.21, 1.22
- ganglioneuroblastoma 43, 5.4, 5.5  
ganglioneuroma 46, 5.10–5.12  
focal lymphocyte infiltration 46, 5.12  
microcysts 46, 5.11  
gastrointestinal tract, Langerhans cell histiocytosis 63  
genitourinary anomalies, Wilms' tumour-associated 26  
genitourinary rhabdomyosarcoma 103  
germ cell tumours 70  
Kooijman classification 70  
germinomas 70, 72, 9.11–9.13  
giant cell fibroblastoma 110  
giant cell tumour, synovial sheath 115, 13.29, 13.30  
gingival granular cell tumour 108, 110, 13.7  
gliomatosis  
nodal 78  
peritonei 78  
glomeruloid bodies 70, 9.5  
glomus tumour (glomangioma) 84, 10.17  
glycogen, intracytoplasmic  
dysgerminomas 72, 9.12  
Ewing's sarcoma 58, 7.11  
gonadotrophin, human chorionic ( $\beta$ -HCG) 72  
granular cell tumour 110  
gingival 108, 110, 13.7  
granulocytic sarcoma (chloroma) 39, 4.24  
granuloma, plasma cell 118
- haemangioendothelioma  
hepatic 16, 1.25–1.28  
intravascular vegetant (Masson) 85, 10.20, 10.21  
Kaposi-like, infantile 85, 88  
malignant 85, 10.22  
spindle cell 84  
haemangiolympangiomas 84  
haemangiomas 81, 10.1–10.8  
capillary 81, 10.1–10.6  
cellular 81, 10.1, 10.2  
epithelioid 84–5, 10.18, 10.19  
histiocytoid 84–5, 10.18, 10.19  
sclerosing 81, 10.5  
skeletal muscle 81, 10.8  
haemangiopericytoma, infantile 81, 84, 10.12–10.16  
spindle cells 84, 10.16  
haemophagocytic reticulosis, congenital 66, 8.16–8.21  
haemophagocytic syndrome, infection-associated 66  
haemopoiesis, extramedullary, fetal hepatoblastoma 9, 1.4  
haemopoietic tissue, Langerhans cell histiocytosis 63  
hamartoma  
fibrous 23, 2.21–2.24  
of infancy (FHI) 92, 11.4, 11.6  
leiomyomatous 23, 2.21–2.24  
mesenchymal  
fetal 23, 2.21–2.24  
liver 13, 16, 1.19, 1.20  
myxoid, omental–mesenteric 118  
neuromuscular 106, 115  
scalp, ectopic meningotheial 114, 13.24  
hamartomatosis, generalized 89, 92, 11.1–11.3  
Hand–Schüller–Christian syndrome 60  
hemihypertrophy, Wilms' tumour-associated 26  
hepatoblastoma 9–12, 1.1–1.10  
anaplastic 12, 1.9  
clinical associations 9  
cytogenetic analysis/flow cytometry 12  
embryonal 9, 1.5–1.7  
epithelial–mesenchymal mixed 12, 1.10  
fetal 9, 1.3, 1.4, 1.6  
hepatocellular carcinoma differentiation 12  
histological subtypes 9–12, 1.3–1.10  
macrotrabecular 9, 12, 1.8  
osteoid-like material 12, 1.10  
prognosis 12  
small cell undifferentiated 12, 1.9  
teratoid 12  
hepatocellular carcinoma 12–13, 1.11  
associated diseases 12–13  
fibrolamellar 13  
hepatoblastoma differentiation 12  
hepatosplenomegaly, familial haemophagocytic lymphohistiocytosis 66, 8.17  
histiocytic granulomas, intracytoplasmic 72, 9.13  
histiocytic lymphoma 38  
histiocytoid haemangioma 84–5, 10.18, 10.19  
histiocytoma  
fibromatous, angiomatoid malignant 111, 13.15, 13.16  
fibrous, malignant (MFH) 118–19  
histiocytosis  
cephalic benign 66  
malignant 67  
cell leukaemia/lymphoma 67  
regressing atypical 67  
histiocytosis X *see* Langerhans cell histiocytosis  
histocytic disorders 60, 8.1–8.24  
Hodgkin's cells 38  
Hodgkin's disease 38–9, 4.15–4.23  
Ann Arbor staging 38  
classification 38  
immunohistochemistry 38  
lacunar cells 38, 4.20, 4.21  
lymphocyte depletion 39  
lymphocyte predominance 39, 4.22  
mixed cellularity 39, 4.23  
nodular sclerosing 38–9, 4.17–4.21  
Reed–Sternberg cells 38, 4.15, 4.19, 4.20  
Homer–Wright rosettes, neuroblastoma 43, 5.2A,B  
homovanillic acid (HVA) 46, 47  
human chorionic gonadotrophin ( $\beta$ -HCG) 72  
hyaline globules, yolk sac tumours 70, 9.6  
hydrops, fetal 74  
hygroma, cystic 84
- inclusion body fibromatosis 92–3, 11.7–11.10  
inflammatory pseudotumour 118  
intracranial teratomas 79  
intrathoracic rhabdomyosarcoma 103
- Kaposi's sarcoma 85  
Ki-1 lymphoma 35, 38, 4.11–4.14  
differential diagnosis 35, 38  
kidney  
rhabdoid tumour 115  
rhabdomyosarcoma 103  
sarcomatous tumours 28  
teratomas 79  
Klippel–Trenaunay–Weber syndrome 81  
Knudson's two-hit hypothesis 66  
Kooijman classification, germ cell tumours 70
- lacunar cells, Hodgkin's disease 38, 4.20, 4.21  
Langerhans cell histiocytosis 60, 62–3  
clinical variants 63  
intertriginous rash 62, 8.12  
lesion cell morphology 60, 8.1  
maculopapular lesions 62, 8.11  
prognosis 63  
siderotic multinucleate cells 60, 8.10  
sites 62–3, 8.8–8.14  
stages 60, 8.5–8.7  
leiomyomas, multiple vascular, of newborn 89, 92, 11.1–11.3  
leiomyomatous hamartoma 23, 2.21–2.24  
Letterer–Siwe disease 60, 66  
leukaemia, acute lymphocytic, T-cell (T-ALL) 34  
lipoblastoma 110, 13.8–13.10  
lipoblastomatosis 110  
liposarcoma 118  
liver  
Langerhans cell histiocytosis 62

- primary tumours 9
  - types 9
- rhabdomyosarcoma 102
- teratomas 78–9
- Lukes' and Butler classification, Rye modification 38
- lung, Langerhans cell histiocytosis 62, 8.14
- lymph nodes, Langerhans cell histiocytosis 62
- lymphangiomas 81, 84, 10.9–10.11
  - cavernous 84
  - cystic 84, 10.9
  - simplex cutaneous 84
- lymphoblastic lymphoma 34, 4.1–4.4
  - CALLA 34
  - common acute, surface antigen (CALLA) 34
- lymphocytic leukaemia, acute T-cell (T-ALL) 34
- lymphocytic lymphoma
  - convoluted 34
  - poorly differentiated, of childhood 34
- lymphohistiocytosis
  - erythrophagocytic 66, 8.16–8.21
  - familial 66, 8.16–8.21
  - haemophagocytic congenital 66, 8.16–8.21
- lymphoma, hepatic 18
- lymphoma, malignant 34–42
  - large-cell 35, 4.11–4.14
  - see also* Hodgkin's disease: non-Hodgkin's lymphoma; *etc.*
- lymphosarcoma, of childhood 34
  
- Masson's vegetant intravascular haemangioendothelioma 85, 10.20, 10.21
- mediastinal teratomas 78
- medulloepithelioma 51
- melanotic neuroectodermal tumour 50–1, 6.7, 6.8
- meningocele, scalp 114, 13.24
- mesenchymal tumours, multiple congenital 89, 92, 11.1–11.3
- mesenchymoma 106, 118, 13.31, 13.32
  - malignant 13, 1.12–1.19
- MRTK *see* rhabdoid tumour, malignant, renal
- multilocular cyst, renal 22, 2.9–2.11
- muscle, skeletal 106
  - haemangiomas 81, 10.8
  - rhabdomyosarcoma 103, 12.17
- myoblastoma 110
- myofibroblastic tumour, inflammatory 118
- myofibroblastoma 118
  - digital infantile 92–3, 11.7–11.10
- myofibromatosis, infantile 89–92, 11.1–11.3
  - differential diagnosis 92
  - sites 89
- myositis, focal 115
- myositis ossificans 115, 13.28
  
- naevoxanthoendothelioma 63, 66, 8.15
- nasopharyngeal angiofibroma 97
- nephroblastoma 106
  - cystic
    - benign 22, 2.9–2.11
    - cellular (atypical) variant 23
    - partially differentiated (CPDN) 22, 2.9–2.11
- nephroblastomatosis 23, 2.18–2.20
  - intralobar 23, 2.18, 2.19
  - nomenclature 22
- nephrogenic rests 22, 2.12–2.20
  - adenomatous 23, 2.17
  - maturing 23, 2.13
  - nephroblastomatous 23, 2.16
- nephroma
  - congenital mesoblastic 19, 23, 2.21–2.24
  - cystic 22, 2.9–2.11
- neurilemmoma 108, 13.4, 13.5
- neuroblastoma 43, 46–7, 5.1–5.14
  - biochemical aspects 46
  - bone marrow involvement 43, 46, 5.6
  - genetic/molecular markers 47
  - Homer–Wright rosettes 43, 5.2A,B
  - immunohistochemistry 46
  - in-situ* 46, 5.7–5.9
  - neuroepithelioma differentiation 50, 51
  - olfactory 51
  - peripheral 50, 6.1–6.6
  - prognostic determinants 46–7
  - staging system 43
  - tissue culture morphology 46
  - tumour cell clumping 43, 5.3
  - ultrastructure 46, 5.13–5.14
  - undifferentiated 43, 5.1, 5.3
- neuroectodermal tumour
  - bone 55
  - melanotic, of infancy 50–1, 6.7, 6.8
- neuroepithelioma 50, 6.1–6.6
  - intra-abdominal 50, 6.3
- neuroblastoma differentiation 50, 51
- neurofibroma 108, 13.1–13.3
  - plexiform 108, 13.3
- neurofibrosarcoma 108, 13.6
- neurothekeoma 108
- N-*myc*, and neuroblastoma prognosis 47
- nodular hyperplasia, focal (FNH), liver 16, 1.21, 1.22
- nodular regenerative hyperplasia, hepatic 18
- non-Hodgkin's lymphoma (NHL) 19, 34–5, 38, 4.1–4.14
  
- omental–mesenteric myxoid hamartoma 118
- orbit, rhabdomyosarcoma 102
- orchioblastoma, infantile 70, 72
- ovarian dermoids 74, 9.24–9.27
  - calcified nodules 74, 9.25, 9.26
  - epithelial lining 74, 9.27
  - lardaceous material/hair 74, 9.24
- ovarian dysgerminomas 72, 9.11–9.13
- ovarian teratoma 74, 78, 9.24–9.27
  - immaturity and metastases 78
- mesodermal 50
- neuroepithelium 78
  
- pancreas, dermoid cysts 79
- pelvis, rhabdomyosarcoma 103
- peripheral nerve sheath tumours
  - benign 108, 13.1–13.5
  - malignant (MPNST) 106, 108, 13.6
- Perleman syndrome 26
- plasma cell granuloma 118
- PNETs 19
- port-wine stains 81
- progonoma, melanotic 50–1, 6.7, 6.8
- pseudotumour, inflammatory 118
- pyroninophilia, Burkitt's lymphoma 35, 4.8
  
- reactive haemophagocytic syndrome (RHS) 66
  - FHL relationship 66–7
- Reed–Sternberg cells
  - Hodgkin's disease 38, 4.15, 4.19, 4.20
  - L&H variant 39, 4.22
  - lacunar-type 38, 4.20, 4.21
  - multinuclear (pleomorphic) 38, 4.19
  - mummified 38, 4.16
- reticulosis
  - haemophagocytic congenital 66, 8.16–8.21
  - histiocytic medullary 67
- retinal anlage tumour 50–1, 6.7, 6.8
- retroperitoneal rhabdomyosarcoma 103
- retroperitoneal teratomas 78
- rhabdoid tumour
  - extrarenal (ERRT) 31, 115, 118
  - kidney 115
- rhabdoid tumour, malignant, renal (MRTK) 19, 30–31, 33, 3.13
  - associated primary tumours 31
  - globular hyaline inclusions 30, 3.11
  - microscopy 30, 3.10, 3.11
  - pathology 30–1, 3.9–3.12
  - ultrastructure 31, 33, 3.13
  - Wilms' tumour differences 31
- rhabdomyoblasts 99, 12.1–12.3, 12.8
- rhabdomyoma, fetal 106, 12.20, 12.21
- rhabdomyosarcoma (RMS) 99
  - actin/myosin filaments 106, 12.18
  - alveolar 99, 102, 12.11–12.16
    - chromosomal translocation 102
    - round cell/solid variant 102, 12.16
  - botryoid 99, 12.4
  - hepatic 102

- differentiation induction *in vitro* 106  
 electron microscopy 103, 106, 12.18, 12.19  
 embryonal 99, 12.4–12.10  
 extremities 103  
 genitourinary 103  
 head and neck 102  
 immunohistochemistry 103, 12.17  
 intermediate filament cytoplasmic inclusions 102  
 intrathoracic 103  
 metastases 102  
 mixed pattern 102  
 myxoid 99, 12.5  
 orbital 102  
 pelvic 103  
 perianal/perineal 103  
 peritoneal 103  
 pleomorphic 102  
 primitive 102  
 renal 103  
 spindle-cell pattern 99, 12.9, 12.10  
 trunk 103  
 Rosai–Dorfman disease 60, 62, 67, 8.22–8.24  
 S-100 protein, Langerhans cell histiocytosis 60, 8.2  
 sacrococcygeal teratoma 74, 9.16–9.23  
   embryonal cartilage 74, 9.21  
   gross appearance 74, 9.16, 9.17  
   growth patterns 74  
   immature liver tissue 74, 9.23  
   immature myogenic tissue 74, 9.22  
   neuroglial tissue 74, 9.18–9.20  
 sarcoma  
   alveolar soft part 114, 13.25  
   clear-cell, kidney 28, 30  
   embryonal, liver 13, 1.12–1.19  
   epithelioid 118  
   granulocytic 39, 4.24  
   mesenchymal, undifferentiated 102  
   synovial 114–15, 13.26, 13.27  
   undetermined histogenesis 102  
   undifferentiated, liver 13, 1.12–1.19  
 scalp, hamartoma, ectopic meningothelial 114, 13.24  
 scapula, Langerhans cell histiocytosis 60, 8.8  
 Schiller–Duval bodies 70, 9.5  
 schwannoma 108, 13.4, 13.5  
   malignant 106, 108, 13.6  
 seminomas, testicular 72  
 sinus histiocytosis, lymphadenopathy *see* Rosai–Dorfman disease  
 skin, Langerhans cell histiocytosis 62, 8.11–8.13  
 skull  
   eosinophilic granuloma, S-100 protein 60, 8.2  
   Langerhans cell histiocytosis 60, 8.9, 8.10  
 small cell tumour  
   desmoplastic, intra-abdominal 51, 6.11, 6.12  
   polyphenotypic, of childhood 51  
   thoracopulmonary region 50, 6.2–6.6  
 spindle cell haemangioendothelioma 84  
 spindle cell tumours, mimicking by rhabdomyosarcoma 99  
 spleen, Langerhans cell histiocytosis 63  
 Sternberg sarcoma 34  
 sternomastoid tumour 93, 11.13  
 stomach, teratomas 78  
 strawberry naevus 81, 10.1–10.6  
 syncytiotrophoblastic cells, choriocarcinoma 72, 9.14  
 synovial sarcoma 114–15, 13.26, 13.27  
   calcification 114, 13.27  
   differential diagnosis 115  
   spindle cell pattern 114, 13.26  
 Teilmumour 70, 72  
 tendon sheath  
   fibroma 115  
   giant cell tumour 115, 13.29, 13.30  
 tenosynovitis, nodular, localized 115, 13.29, 13.30  
 teratomas 70, 106  
   abdominal 78  
   classification 70  
   craniocervical 74  
   fetus-in-fetu 70  
   intracranial 79  
   kidney 19, 79  
   liver 78–9  
   mediastinal 78  
   mesodermal, ovarian 50  
   ovarian 50, 74, 78, 9.24–9.27  
   retroperitoneal 78  
   sacrococcygeal 74, 9.16–9.23  
   stomach 78  
   testicular 78  
 testis  
   seminomas 72  
   teratomas 78  
 thoracopulmonary region, small-cell tumour 50, 6.2–6.6  
 thymocyte-related antigen (CD1; T6), Langerhans cell histiocytosis 60, 8.3  
 thymus, Langerhans cell histiocytosis 63  
 torticollis, congenital 93, 11.13  
 Touton-type giant cells 63, 8.15  
 Triton tumour 106, 108  
   benign 115  
 trunk, rhabdomyosarcoma 103  
 tyrosinaemia, hepatocellular carcinoma-associated 12  
 vagina, polyps 106  
 vanilylmandelic acid (VMA) 46, 47  
 varicosities, haemangiomatous 81  
 vimentin, MRTK 31, 3.12  
 von Recklinghausen's neurofibromatosis (VRN) 26, 108  
 WAGR syndrome 26  
 Wilms' tumour  
   anaplastic 19, 22  
   associated syndromes 26  
   BMRTC differences 33  
   cut surface 19, 2.1  
   differential diagnosis 19, 2.4  
   DNA index, and prognosis 22  
   epithelial differentiation 19, 2.4  
   extrarenal 26  
   fetal rhabdomyomatous 22, 2.7, 2.8  
   incidence 19  
   metanephric blastema 19, 2.3  
   microscopic pattern 19, 2.2  
   monomorphous epithelial 19, 2.5  
   MRTK differences 31  
   presentation 19  
   rhabdomyosarcomatid pattern 30–1  
   teratoid 23  
   *see also* nephroblastoma  
 xanthogranuloma, juvenile (JXG) 63, 66, 8.15  
 yolk sac carcinoma 70, 72  
 yolk sac tumours 70, 72, 9.1–9.8  
   cellular patterns 70, 9.1–9.4, 9.8  
   hyaline globules 70, 9.6  
   immunohistochemistry 72  
   and mixed teratomas 72, 9.8  
   mucoid mesenchymal component 70, 9.7  
   Schiller–Duval bodies 70, 9.5  
   sites 70